Does anyone know about the status of the RadioGel resubmission? Last time in the CC, they mentioned about filing the medical device application in the next 60 days ... Like to hear from the company.
I understand the business strategy of providing free copay for a year should not be a problem with enough capital, but will this be a double jeopardy at this stage if we were to go alone?
RSI(14) is now below 15. I picked some shares today at 1.75 thinking it would be the bottom of the well, but apparently I was wrong. I was out 50% after Q2 CC, bought back in today to average down, I have another 20% more to invest then I am done. It is very frustrating to see this depreciation. The charts never lie, and right now we are now 50% below oversold territory, which is a very rare situation. This is worser than receiving a CRL or results from phase III not meeting the primary / secondary end points. For god sakes, we have an FDA approved drug which is preparing to launch this quarter. Very strange.
Even after all this, we see no guidance from the management. They are unbelievable. I saw someone was speculating that news might have leaked with offering at 1.50, I think that is plausible.
You can read that as many time as you want to make you feel comfortable with your investment, but "at the end of the day" it is the execution from our CEO that can make the difference.
$5M is worth more than the market cap of the company. If they were to raise that much money, they may issue 50M shares at 0.1 pps to a private investor which will work for both sides.
I understand the frustration. The management has done a horrible job, they need to be honest to their investors, instead they have been keeping us in the dark, I see hype after hype from the management for literally nothing other than to trap investors. I sold half of my position with a loss after Q2 conference call. I want to make a reentry but can not predict the bottom of the well..
I suspect NuPathe is working with some hedge fund institutions to drag the price below $2 warrant for some profit. I have been saying this on and on again, PATH above $2 is of little interest to the market. Things will start picking up once it goes below $1.7, the volume will increase, wall street will dive in, day traders will chip in, the PUTS options will be exercised. Expect bleeding to continue for the next week or two before we rebound.
Lots of downside still left. I am afraid that the price is heading down and will go below $2 quite easily. Currently, there is absolutely no interest from the market and retailers, and this is the problem. The hype that you see from the CEO and a few pumpers is trapping investors, most of you just don't realize this. The market will have no interest until the price is below the $2 warrants. When it reaches $1.5-$1.7, then you will start seeing articles from analyst, wall street upgrade, institution upgrade, Armando stepping up, etc., and the same pumpers in this board will buy back. Until then, be prepared to ride the bleeding phase.
You are right. I have started to loose faith on the company, maybe the market has absolutely no interest on the product. Maybe the product is not as good as advertised. Maybe the market fears the company to go alone which can further dilute the shares. There is just a lot of speculation, on top of everything, management has done a poor job in communicating to their investors.
Yes, I have realized that. They are frustrated and angry for buying at higher rates. I just don't understand why they need to bash more, they get nothing in return unless they want the share price to further dip and then buy to average down more.
Sentiment: Strong Buy
Useless. That is someone's tweet, maybe an investor or a pumper. We desperately need a PR from the management, something good for investors to cheer and be assured about. Rest nothing will stop the bleeding.
In my opinion, Armando thinks too big about NuPathe. He is extremely confident and is demanding a very high premium. Migraine treatment is a very competitive market which is why it is getting extremely tough to find a partner that thinks as high as Armando. I value this company not more than 300M. I think the annual 1M sale is another hype from the CEO, I will be glad to see 300,000 units sold annually. You would imagine that there were lots of deals which Armando turned down because of his ego, this may prove very costly for the retail investors. I am hoping we get a deal in a month or two.